Key facts
- This page summarizes Keith Katkin's Form 4 filing for Eledon Pharmaceuticals, Inc. (ELDN).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Jan 2025, 17:30.
Keith Katkin - 10 Jan 2025 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)
- Reporting relationship
- Director
- Issuer ticker
- ELDN
- Reported as of
- 10 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jan 2025, 17:30:07 UTC
- Prior SEC filing
- 28 May 2024
- Next SEC filing
- 07 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Paul Little, as attorney-in-fact for Keith Katkin
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Keith Katkin filed Form 4 for Eledon Pharmaceuticals, Inc. (ELDN) on 13 Jan 2025.
Change
- Previous filing in this sequence was filed on 28 May 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ELDN
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +77,175
- Change %
- Price
- $0.000000
- Shares after
- 77,175
- Date
- 10 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 77,175
- Exercise price
- $4.04
- Footnotes
- F1
ELDN
transaction
Derivative
Restricted Stock Units
Award
- Transaction value
- $0
- Shares
- +8,575
- Change %
- Price
- $0.000000
- Shares after
- 8,575
- Date
- 10 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,575
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
This option represents a right to purchase up to 77,175 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026.
Footnote F2
Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration.
Footnote F3
100% of the restricted stock units will vest on January 10, 2026.